丹参酮在多囊卵巢综合征治疗中的潜在价值及其机制

doi:10.12280/gjszjk.20240275

摘要/Abstract

摘要：

丹参酮是从中药丹参中提取的一类化合物，因其抗炎、抗氧化及抗癌特性而备受关注。近期研究表明，丹参酮在多囊卵巢综合征（polycystic ovary syndrome，PCOS）的治疗中具有潜在价值。丹参酮可能通过调节激素平衡、增强胰岛素敏感性以及减轻炎症反应等机制，有效改善PCOS患者的胰岛素抵抗、脂质代谢异常、高雄激素血症和慢性低度炎症等症状。此外，丹参酮还能改善PCOS患者排卵障碍和卵巢功能不全。综述近年来丹参酮在PCOS治疗领域的研究进展，以期为PCOS临床实践和新药研发提供理论参考。

关键词: 丹参酮, 多囊卵巢综合征, 作用机制, 隐丹参酮, 丹参酮ⅡA

Abstract:

Tanshinone is a type of compound extracted from the traditional Chinese medicine Salvia miltiorrhiza, and it has received considerable attention due to its anti-inflammatory, antioxidant, and anti-cancer properties. Recent studies have suggested that tanshinone holds potential value in the treatment of polycystic ovary syndrome(PCOS). Tanshinone may effectively improve the insulin resistance, abnormal lipid metabolism, hyperandrogenemia, and chronic low-grade inflammation in PCOS patients by regulating hormone balance, enhancing insulin sensitivity, and reducing inflammatory responses. In addition, tanshinone can also improve ovulation disorders and ovarian dysfunction in PCOS patients. This article aims to review the research progress of tanshinone in the treatment of PCOS in recent years, in order to provide a theoretical reference for clinical practice and new drug development for PCOS.

Key words: Tanshinone, Polycystic ovary syndrome, Mechanism of action, Cryptotanshinone, Tanshinon ⅡA

李安琪, 朱梦一, 王宇, 高敬书, 吴效科. 丹参酮在多囊卵巢综合征治疗中的潜在价值及其机制[J]. 国际生殖健康/计划生育杂志, 2024, 43(6): 494-500.

LI An-qi, ZHU Meng-yi, WANG Yu, GAO Jing-shu, WU Xiao-ke. Potential Application of Tanshinone in the Treatment of Polycystic Ovary Syndrome and Mechanism[J]. Journal of International Reproductive Health/Family Planning, 2024, 43(6): 494-500.

参考文献 45

[1]	Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment[J]. Nat Rev Endocrinol, 2018, 14(5):270-284. doi: 10.1038/nrendo.2018.24. pmid: 29569621
[2]	Bril F, Ezeh U, Amiri M, et al. Adipose Tissue Dysfunction in Polycystic Ovary Syndrome[J]. J Clin Endocrinol Metab, 2023, 109(1):10-24. doi: 10.1210/clinem/dgad356. pmid: 37329216
[3]	Huang Z, Xu T, Liu C, et al. Correlation between ovarian follicular development and Hippo pathway in polycystic ovary syndrome[J]. J Ovarian Res, 2024, 17(1):14. doi: 10.1186/s13048-023-01305-z. pmid: 38216976
[4]	Ayvazyan A, Deutsch L, Zidorn C, et al. Cytotoxic diterpenoids from Salvia glutinosa and comparison with the tanshinone profile of danshen (Salvia miltiorrhiza)[J]. Front Plant Sci, 2023,14:1269710. doi: 10.3389/fpls.2023.1269710.
[5]	Shen W, Zhang Y, Li W, et al. Effects of tanshinone on hyperandrogenism and the quality of life in women with polycystic ovary syndrome: protocol of a double-blind, placebo-controlled, randomised trial[J]. BMJ Open, 2013, 3(10):e003646. doi: 10.1136/bmjopen-2013-003646. pmid: 24163207
[6]	Tong C, Wu Y, Zhang L, et al. Insulin resistance, autophagy and apoptosis in patients with polycystic ovary syndrome: Association with PI3K signaling pathway[J]. Front Endocrinol(Lausanne), 2022, 13:1091147. doi: 10.3389/fendo.2022.1091147.
[7]	Zheng Y, Zhou X, Wang C, et al. Effect of Tanshinone ⅡA on Gut Microbiome in Diabetes-Induced Cognitive Impairment[J]. Front Pharmacol, 2022,13:890444. doi: 10.3389/fphar.2022.890444.
[8]	虎亚光, 岳嘉, 李金娟, 等. 丹参酮胶囊对多囊卵巢综合征大鼠糖脂代谢及性激素的影响[J]. 中国药房, 2016, 27(19):2632-2634. doi: 10.6039/j.issn.1001-0408.2016.19.13.
[9]	匡洪影, 马珂昕, 李威, 等. 隐丹参酮调节PCOS模型大鼠卵巢颗粒细胞生殖内分泌机能的机制研究[J]. 中医药学报, 2017, 45(5):40-44. doi: 10.3969/j.issn.1002-2392.2017.05.010.
[10]	Jung SH, Seol HJ, Jeon SJ, et al. Insulin-sensitizing activities of tanshinones, diterpene compounds of the root of Salvia miltiorrhiza Bunge[J]. Phytomedicine, 2009, 16(4):327-335. doi: 10.1016/j.phymed.2008.12.017. pmid: 19200697
[11]	Jung DY, Kim JH, Jung MH. Anti-Obesity Effects of Tanshinone Ⅰfrom Salvia miltiorrhiza Bunge in Mice Fed a High-Fat Diet through Inhibition of Early Adipogenesis[J]. Nutrients, 2020, 12(5):1242. doi: 10.3390/nu12051242.
[12]	Hwang SL, Yang JH, Jeong YT, et al. Tanshinone ⅡA improves endoplasmic reticulum stress-induced insulin resistance through AMP-activated protein kinase[J]. Biochem Biophys Res Commun, 2013, 430(4):1246-1252. doi: 10.1016/j.bbrc.2012.12.066.
[13]	Yang X, Zhang Y, Wu X, et al. Cryptotanshinone reverses reproductive and metabolic disturbances in prenatally androgenized rats via regulation of ovarian signaling mechanisms and androgen synthesis[J]. Am J Physiol Regul Integr Comp Physiol, 2011, 300(4):R869-R875. doi: 10.1152/ajpregu.00334.2010.
[14]	Pinky, Neha, Salman M, et al. Age-related pathophysiological alterations in molecular stress markers and key modulators of hypoxia[J]. Ageing Res Rev, 2023,90:102022. doi: 10.1016/j.arr.2023.102022.
[15]	Zhou Y, Zhang H, Huang Y, et al. Tanshinone ⅡA regulates expression of glucose transporter 1 via activation of the HIF-1α signaling pathway[J]. Mol Med Rep, 2022, 26(5):328. doi: 10.3892/mmr.2022.12844.
[16]	Huang Y, Li W, Wang CC, et al. Cryptotanshinone reverses ovarian insulin resistance in mice through activation of insulin signaling and the regulation of glucose transporters and hormone synthesizing enzymes[J]. Fertil Steril, 2014, 102(2):589-596.e4. doi: 10.1016/j.fertnstert.2014.05.012. pmid: 24973798
[17]	王娜梅. 隐丹参酮对多囊卵巢综合征大鼠糖脂代谢及性激素的影响[J]. 中国妇幼保健, 2015, 30(20):3490-3493. doi: 10.7620/zgfybj.j.issn.1001-4411.2015.20.60.
[18]	Heidarzadehpilehrood R, Pirhoushiaran M, Abdollahzadeh R, et al. A Review on CYP11A1, CYP17A1, and CYP19A1 Polymorphism Studies: Candidate Susceptibility Genes for Polycystic Ovary Syndrome (PCOS) and Infertility[J]. Genes (Basel), 2022, 13(2):302. doi: 10.3390/genes13020302.
[19]	Ye D, Li M, Zhang Y, et al. Cryptotanshinone Regulates Androgen Synthesis through the ERK/c-Fos/CYP17 Pathway in Porcine Granulosa Cells[J]. Evid Based Complement Alternat Med, 2017, 2017:5985703. doi: 10.1155/2017/5985703.
[20]	王宇, 胡敏, 张跃辉, 等. 隐丹参酮对Akt2基因缺失雌鼠生殖功能及其效应机制的影响[J]. 中国中西医结合杂志, 2019, 39(5):577-582. doi: 10.7661/j.cjim.20190201.102.
[21]	熊曙康, 李威, 张丹, 等. 卵泡膜细胞胰岛素抵抗及隐丹参酮的调控[J]. 中华中医药杂志, 2012, 27(6):1639-1642.
[22]	祁冰, 宋家欣, 杨琳, 等. 基因芯片研究隐丹参酮对胰岛素抵抗卵巢颗粒细胞基因表达的影响[J]. 科技导报, 2009, 27(15):39-43. doi: 10.3321/j.issn:1000-7857.2009.15.007.
[23]	Qian Y, Tong Y, Zeng Y, et al. Integrated lipid metabolomics and proteomics analysis reveal the pathogenesis of polycystic ovary syndrome[J]. J Transl Med, 2024, 22(1):364. doi: 10.1186/s12967-024-05167-x. pmid: 38632610
[24]	Peng Y, Zhao L, Li M, et al. Plasticity of Adipose Tissues: Interconversion among White, Brown, and Beige Fat and Its Role in Energy Homeostasis[J]. Biomolecules, 2024, 14(4):483. doi: 10.3390/biom14040483.
[25]	Lemaitre M, Christin-Maitre S, Kerlan V. Polycystic ovary syndrome and adipose tissue[J]. Ann Endocrinol (Paris), 2023, 84(2):308-315. doi: 10.1016/j.ando.2022.11.004.
[26]	Ma L, Zhao Z, Guo X, et al. Tanshinone ⅡA and its derivative activate thermogenesis in adipocytes and induce "beiging" of white adipose tissue[J]. Mol Cell Endocrinol, 2022,544:111557. doi: 10.1016/j.mce.2022.111557.
[27]	Villarroya F, Peyrou M, Giralt M. Transcriptional regulation of the uncoupling protein-1 gene[J]. Biochimie, 2017, 134:86-92. doi: 10.1016/j.biochi.2016.09.017. pmid: 27693079
[28]	Luo J, Yu Z, Tovar J, et al. Critical review on anti-obesity effects of phytochemicals through Wnt/β-catenin signaling pathway[J]. Pharmacol Res, 2022,184:106461. doi: 10.1016/j.phrs.2022.106461.
[29]	Park YK, Obiang-Obounou BW, Lee J, et al. Anti-Adipogenic Effects on 3T3-L1 Cells and Zebrafish by Tanshinone ⅡA[J]. Int J Mol Sci, 2017, 18(10):2065. doi: 10.3390/ijms18102065.
[30]	Rahman N, Jeon M, Song HY, et al. Cryptotanshinone, a compound of Salvia miltiorrhiza inhibits pre-adipocytes differentiation by regulation of adipogenesis-related genes expression via STAT3 signaling[J]. Phytomedicine, 2016, 23(1):58-67. doi: 10.1016/j.phymed.2015.12.004. pmid: 26902408
[31]	Wu YL, Lin H, Li HF, et al. Salvia miltiorrhiza Extract and Individual Synthesized Component Derivatives Induce Activating-Transcription-Factor-3-Mediated Anti-Obesity Effects and Attenuate Obesity-Induced Metabolic Disorder by Suppressing C/EBPα in High-Fat-Induced Obese Mice[J]. Cells, 2022, 11(6):1022. doi: 10.3390/cells11061022.
[32]	Orisaka M, Mizutani T, Miyazaki Y, et al. Chronic low-grade inflammation and ovarian dysfunction in women with polycystic ovarian syndrome, endometriosis, and aging[J]. Front Endocrinol (Lausanne), 2023,14:1324429. doi: 10.3389/fendo.2023.1324429.
[33]	Yang Y, Yang L, Qi C, et al. Cryptotanshinone alleviates polycystic ovary syndrome in rats by regulating the HMGB1/TLR4/NF-κB signaling pathway[J]. Mol Med Rep, 2020, 22(5):3851-3861. doi: 10.3892/mmr.2020.11469.
[34]	陈静, 李威, 吴奇, 等. 小鼠卵巢器官的胰岛素抵抗及中药隐丹参酮的调控作用[J]. 医学研究生学报, 2015, 28(5):475-479. doi: 10.3969/j.issn.1008-8199.2015.05.006.
[35]	Talotta F, Casalino L, Verde P. The nuclear oncoprotein Fra-1: a transcription factor knocking on therapeutic applications′ door[J]. Oncogene, 2020, 39(23):4491-4506. doi: 10.1038/s41388-020-1306-4.
[36]	Liu H, Zhou J, Xie J, et al. Tanshinone ⅡA as a therapy for PCOS via FOS/JUN/TP53 axis: Evidence from network pharmacology of Bajitian-Danshen pair[J]. Arab J Chem, 2024, 17(4):105641. doi: 10.1016/j.arabjc.2024.105641.
[37]	Lörincz CE, Börzsei D, Hoffmann A, et al. Mechanisms and Target Parameters in Relation to Polycystic Ovary Syndrome and Physical Exercise: Focus on the Master Triad of Hormonal Changes, Oxidative Stress, and Inflammation[J]. Biomedicines, 2024, 12(3):560. doi: 10.3390/biomedicines12030560.
[38]	Xu R, Wang Z. Involvement of Transcription Factor FoxO1 in the Pathogenesis of Polycystic Ovary Syndrome[J]. Front Physiol, 2021, 12:649295. doi: 10.3389/fphys.2021.649295.
[39]	Xiang Y, Wang H, Ding H, et al. Hyperandrogenism drives ovarian inflammation and pyroptosis: A possible pathogenesis of PCOS follicular dysplasia[J]. Int Immunopharmacol, 2023, 125(Pt A):111141. doi: 10.1016/j.intimp.2023.111141.
[40]	Miao Q, Wang R, Sun X, et al. Combination of puerarin and tanshinone ⅡA alleviates ischaemic stroke injury in rats via activating the Nrf2/ARE signalling pathway[J]. Pharm Biol, 2022, 60(1):1022-1031. doi: 10.1080/13880209.2022.2070221.
[41]	Liu QY, Zhuang Y, Song XR, et al. Tanshinone ⅡA prevents LPS-induced inflammatory responses in mice via inactivation of succinate dehydrogenase in macrophages[J]. Acta Pharmacol Sin, 2021, 42(6):987-997. doi: 10.1038/s41401-020-00535-x.
[42]	Chełchowska M, Jurczewska J, Gajewska J, et al. Antioxidant Defense Expressed as Glutathione Status and Keap1-Nrf2 System Action in Relation to Anthropometric Parameters and Body Composition in Young Women with Polycystic Ovary Syndrome[J]. Antioxidants(Basel), 2023, 12(3):730. doi: 10.3390/antiox12030730.
[43]	Bai L, He G, Gao C, et al. Tanshinone ⅡA enhances the ovarian reserve and attenuates ovarian oxidative stress in aged mice[J]. Vet Med Sci, 2022, 8(4):1617-1625. doi: 10.1002/vms3.811.
[44]	Fu K, Feng C, Shao L, et al. Tanshinone ⅡA exhibits anti-inflammatory and antioxidative effects in LPS-stimulated bovine endometrial epithelial cells by activating the Nrf2 signaling pathway[J]. Res Vet Sci, 2021, 136:220-226. doi: 10.1016/j.rvsc.2021.03.004.
[45]	Li XX, Zheng X, Liu Z, et al. Cryptotanshinone from Salvia miltiorrhiza Bunge (Danshen) inhibited inflammatory responses via TLR4/MyD88 signaling pathway[J]. Chin Med, 2020,15:20. doi: 10.1186/s13020-020-00303-3.